logo BDSP

Base documentaire


Votre avis nous intéresse

Le réseau BDSP met en oeuvre un projet d'innovation et d'amélioration de ses services, dans le souci constant de proposer des contenus de qualité adaptés aux besoins des utilisateurs.

Identifier de nouvelles sources de financements est la condition nécessaire pour assurer la poursuite et la pérennité de cet outil unique qu'est la BDSP, tout en le faisant évoluer.

Pour définir un nouveau modèle économique, nous avons besoin de votre avis : merci de répondre à notre enquête (temps estimé : 5 minutes).

Participer maintenant
Participer plus tard J'ai déjà participé

  1. Influence of age at infection on human immunodeficiency virus disease progression to different clinical endpoints : The SEROCO cohort (1988-1994).

    Article - En anglais

    Method

    The influence of age at infection on progression of human immunodeficiency virus (HIV) disease to different clinical endpoints was studied among 393 HIV-seropositive adults selected from the French SEROCO cohort ; follow-up lasted from January 1988 to November 1994.

    Selected patients had a known date of infection and were enrolled shortly after seroconversion.

    Age-associated risk ratios (RR) were estimated using the Cox model (age fitted as a continuous variable and RR expressed for each 10-year increment after adjustment for symptomatic primary infection and sexual preference).

    Results

    Age had a weak influence on progression from the date of infection to the first category B event (crude RR=1.15 ; adjusted RR=1.09 ; 95% confidence interval [Cl] : 0.89-1.36) but a marked influence on progression from the first category B to the first category C event (crude RR=1.95 ; adjusted RR=1.97 ; 95% Cl : 1.37-2.79).

    Similar results were obtained after adjustment for the CD4+cell count at enrolment.

    A qualitative CD4+cell defect could explain the influence of age, but this remains to be confirmed.

    Conclusion

    Age at infection should be included in the definition of CD4+cell count thresholds for clinical management and treatment initiation.

    Risk factors for progression should be assessed according to the different clinical endpoints.

    Mots-clés Pascal : SIDA, Virose, Infection, Evolution, Numération, Lymphocyte, Epidémiologie, Homme, Facteur risque, Age, Etude cohorte, Immunopathologie, Immunodéficit, Antigène CD4

    Mots-clés Pascal anglais : AIDS, Viral disease, Infection, Evolution, Numeration, Lymphocyte, Epidemiology, Human, Risk factor, Age, Cohort study, Immunopathology, Immune deficiency

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 98-0056878

    Code Inist : 002B05C02D. Création : 14/05/1998.